For instance, PARP1 inhibitors (olaparib, rucaparib, niraparib, and talazoparib) are approved by the Food and Drug Administration (FDA) for clinical use in ovarian or breast cancer, and the variety of treated tumors is growing. Here, PARP1 is linked to breast carcinoma.